Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/36366
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Visser, M | - |
dc.contributor.author | Charleer, S | - |
dc.contributor.author | FIEUWS, Steffen | - |
dc.contributor.author | Hilbrands, R | - |
dc.contributor.author | Maes, T | - |
dc.contributor.author | De Block, C | - |
dc.contributor.author | Vanhaverbeke, G | - |
dc.contributor.author | Dirinck, E | - |
dc.contributor.author | Myngheer, N | - |
dc.contributor.author | Nobels, F | - |
dc.contributor.author | Keymeulen, B | - |
dc.date.accessioned | 2022-01-03T15:03:11Z | - |
dc.date.available | 2022-01-03T15:03:11Z | - |
dc.date.issued | 2021 | - |
dc.date.submitted | 2021-09-14T09:27:59Z | - |
dc.identifier.citation | Diabetes technology & therapeutics, 23 (S2) , p. A30 -A31 | - |
dc.identifier.issn | 0140-6736 | - |
dc.identifier.uri | http://hdl.handle.net/1942/36366 | - |
dc.description.abstract | Background People with type 1 diabetes can continuously monitor their glucose levels on demand (intermittently scanned continuous glucose monitoring [isCGM]), or in real time (real-time continuous glucose monitoring [rtCGM]). However, it is unclear whether switching from isCGM to rtCGM with alert functionality offers additional benefits. Therefore, we did a trial comparing rtCGM and isCGM in adults with type 1 diabetes (ALERTT1).Methods We did a prospective, double-arm, parallel-group, multicentre, randomised controlled trial in six hospitals in Belgium. Adults with type 1 diabetes who previously used isCGM were randomly assigned (1:1) to rtCGM (intervention) or isCGM (control). Randomisation was done centrally using minimisation dependent on study centre, age, gender, glycated haemoglobin (HbA(1c)), time in range (sensor glucose 3.9-10.0 mmol/L), insulin administration method, and hypoglycaemia awareness. Participants, investigators, and study teams were not masked to group allocation. Primary endpoint was mean between-group difference in time in range after 6 months assessed in the intention-to-treat sample. This trial is registered with ClinicalTrials.gov, NCT03772600.Findings Between Jan 29 and July 30, 2019, 269 participants were recruited, of whom 254 were randomly assigned to rtCGM (n=127) or isCGM (n=127); 124 and 122 participants completed the study, respectively. After 6 months, time in range was higher with rtCGM than with isCGM (59.6% vs 51.9%; mean difference 6.85 percentage points [95% CI 4.36-9.34]; p<0.0001). After 6 months HbA(1c) was lower (7.1% vs 7.4%; p<0.0001), as was time <3.0 mmol/L (0.47% vs 0.84%; p=0.0070), and Hypoglycaemia Fear Survey version II worry subscale score (15.4 vs 18.0; p=0.0071). Fewer participants on rtCGM experienced severe hypoglycaemia (n=3 vs n=13; p=0.0082). Skin reaction was more frequently observed with isCGM and bleeding after sensor insertion was more frequently reported by rtCGM users.Interpretation In an unselected adult type 1 diabetes population, switching from isCGM to rtCGM significantly improved time in range after 6 months of treatment, implying that clinicians should consider rtCGM instead of isCGM to improve the health and quality of life of people with type 1 diabetes. Copyright (C) 2021 Elsevier Ltd. All rights reserved. | - |
dc.language.iso | en | - |
dc.publisher | MARY ANN LIEBERT, | - |
dc.rights | 2021 Dexcom, Inc. All rights reserved. | - |
dc.subject.other | Bonheiden | - |
dc.subject.other | Endocrinology | - |
dc.subject.other | Belgium | - |
dc.subject.other | 6 University Hospital Antwerp | - |
dc.subject.other | Endocrinology-diabetology-metabolism | - |
dc.subject.other | Edegem | - |
dc.subject.other | 7 AZ Groeninge | - |
dc.subject.other | Kortrijk | - |
dc.subject.other | 8 OLV Hospital Aalst | - |
dc.subject.other | Aalst | - |
dc.subject.other | 9 Fonds Wetenschappelijk Onderzoek | - |
dc.subject.other | Senior Clinical Investigator Fellow | - |
dc.subject.other | Brussels | - |
dc.title | Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes:the six-month multicenter randomized controlled Alertt1 trial | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | A31 | - |
dc.identifier.issue | S2 | - |
dc.identifier.spage | A30 | - |
dc.identifier.volume | 23 | - |
local.bibliographicCitation.jcat | M | - |
local.publisher.place | INC 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
dc.identifier.isi | 000656638700094 | - |
local.provider.type | - | |
local.uhasselt.international | no | - |
item.accessRights | Restricted Access | - |
item.contributor | Visser, M | - |
item.contributor | Charleer, S | - |
item.contributor | FIEUWS, Steffen | - |
item.contributor | Hilbrands, R | - |
item.contributor | Maes, T | - |
item.contributor | De Block, C | - |
item.contributor | Vanhaverbeke, G | - |
item.contributor | Dirinck, E | - |
item.contributor | Myngheer, N | - |
item.contributor | Nobels, F | - |
item.contributor | Keymeulen, B | - |
item.fullcitation | Visser, M; Charleer, S; FIEUWS, Steffen; Hilbrands, R; Maes, T; De Block, C; Vanhaverbeke, G; Dirinck, E; Myngheer, N; Nobels, F & Keymeulen, B (2021) Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes:the six-month multicenter randomized controlled Alertt1 trial. In: Diabetes technology & therapeutics, 23 (S2) , p. A30 -A31. | - |
item.fulltext | With Fulltext | - |
crisitem.journal.issn | 1520-9156 | - |
crisitem.journal.eissn | 1557-8593 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ATTD 2021 Invited Speaker Abstracts.pdf Restricted Access | Published version | 126.39 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.